Press release & events

Gearing up for ASCO 2022 event! Meet Explicyte in Chicago!

05 / 19 / 2022

Gearing up for ASCO 2022 event! Meet Explicyte in Chicago!

From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.

It’s time to download our posters presented at AACR 2022!

04 / 21 / 2022

It’s time to download our posters presented at AACR 2022!

Back from the AACR 2022, it was a pleasure to take part in it and to converse about our posters showcasing our newest preclinical and translational research advances in Immuno-Oncology.

If you didn't get the chance to meet us and see our posters, or if you want to review them, you can directly download them from the form below.

We'll be there! Meet Explicyte at AACR event in New Orleans

03 / 29 / 2022

We'll be there! Meet Explicyte at AACR event in New Orleans

We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there,  approach your research projects and introduce our service offerings. We will also presentsome scientific posters to highlight our latest innovative preclinical and translational research advances.

Strenghten your immuno-oncology research with our complete digital pathology capacities

03 / 24 / 2022

Strenghten your immuno-oncology research with our complete digital pathology capacities

Drawing on our expertise in multiplexed-immunohistofluoresence (IHF) and immunohistochemistry (IHC) assays, we have already developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets. While bringing key answers to address specific questions, our capacities have recently been highlighted in new scientific publications of collaborative works with Institut Bergonié, which we are delighted to share thereafter.

Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology

03 / 10 / 2022

Domain Therapeutics and Explicyte enter  partnership agreement in immuno-oncology

Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed.

CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth RHU call

01 / 27 / 2022

CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth RHU call

January 27, 2022 – The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5), selected from the 89 applications submitted. This €30M ($34M) project will benefit from a grant of more than €9.8M ($11.1M) to implement a multi-modal project combining precision medicine and immunotherapies for the management of patients with Soft Tissue Sarcomas (STS).